BioRem (BRM) Q1 2026 earnings summary

Executive summary

• Achieved record $77 million order backlog as of March 31, 2026, with 18 new projects secured across Canada, the US, and the Middle East.

• Revenue for Q1 2026 increased 44% year-over-year to $6.8 million, reflecting strong market demand and seasonal construction schedules.

• Management highlights strong bidding activity, diverse technologies, and geographic markets as key growth drivers.

Financial highlights

• Q1 2026 revenue was $6.8 million, up from $4.7 million in Q1 2025.

• Gross profit rose to $1.4 million (20% margin), compared to $1.1 million (23% margin) in Q1 2025.

• EBITDA reached $399,000, up from $229,000 in the prior year quarter.

• Net earnings were $201,000, compared to $37,000 in Q1 2025.

• Basic EPS was $0.012, up from $0.002 year-over-year.

Outlook and guidance

• Management expects continued growth, citing strong backlog, robust bidding, and market demand.

• Company is positioned to manage geopolitical, tariff, and inflationary pressures due to a diverse supply chain and North American manufacturing.